Assessment of QSant™ for Underlying Allograft Rejection

Launched by NEPHROSANT · Mar 8, 2022

Keywords

ClinConnect Summary

The AQUA registry is a clinical trial that aims to study the use of a new test called QSant™ in managing kidney transplant recipients who may be experiencing problems with their transplant. This test looks at specific markers in the urine, including cell-free DNA, to help doctors determine if a kidney transplant is being rejected or if there are other issues. The trial is observational, meaning it will gather information without changing how patients are treated, and it's set to begin recruiting participants soon.

To be eligible for this study, you must be a kidney transplant recipient who had the transplant within the last 90 days. This includes people who may have received other organ transplants along with their kidney. Participants need to be able to understand the risks of joining the study and provide consent. However, individuals who have certain urinary issues or cannot provide a urine sample as required will not be able to participate. If you join, you can expect to provide urine samples for testing and be part of a larger effort to improve kidney transplant care.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Kidney transplant recipient, ≤ 90 days post kidney transplant of any age, solitary or combined multi-organ solid transplants which includes a kidney transplant.
• • 2. Able to understand risks and requirements of participation and provide informed consent
• • 3. Willing and able to comply with the study requirements
• Exclusion Criteria:
• • 1. Inability to provide a voided urine sample per collection protocol
• • 2. Urological abnormalities such as augmented bladder, ileo-conduits, mitrofanoff, and vesicostomy.